In patients who were on oxygen when they first got the drug, remdesivir - sold under the brand Veklury - reduced recovery time by seven days compared with placebo after 29 days, according to the 1,062-patient study, published in the New England Journal of Medicine. The final study looked at data at 29 days of treatment, versus a preliminary study released in May that reported results after 15 days. Remdesivir received emergency use authorization from the US Food and Drug Administration on May 1, and has since been authorized for use in several other countries. Results of the overall study suggested the drug may reduce mortality, but the benefit was not statistically significant. In a separate analysis looking just at patients who received oxygen, however, the drug appeared to reduce the risk of death by 72 percent at day 15, and 70 percent by day 29.

Source: bd News24 October 08, 2020 21:33 UTC